GlassScriptPhysician profile
Sandip S Patel
NPI 1750358222
$34,419.65
in general payments reported to CMS, 2019-2025
33 companies · $704 in 2025
The $704 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $10K · 2021: $13K · 2022: $8,623 · 2023: $710 · 2024: $469 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28,876.08 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $900.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $498.16 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $440.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $382.33 | 2019-2023 | |
| Pfizer INC. | $372.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.43 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $275.04 | 2019-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $264.66 | 2019-2023 | Xarelto |
| Abbvie INC. | $223.59 | 2021-2024 | |
| Exact Sciences Corporation | $213.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $203.05 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $201.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $197.42 | 2019-2025 | |
| Amgen INC. | $183.12 | 2019-2025 | Krystexxa, Repatha, Otezla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $138.88 | 2019-2020 | |
| Astellas Pharma US INC | $124.02 | 2022-2024 | Veozah |
| Allergan, INC. | $69.94 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.37 | 2022-2025 | Xifaxan, Trulance |
| Organogenesis INC. | $60.05 | 2022-2025 | Apligraf |
| Abbott Laboratories | $59.32 | 2021-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $41.34 | 2020-2021 | |
| Edwards Lifesciences Corporation | $35.09 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $34.38 | 2020-2021 | |
| Inspire Medical Systems, INC. | $33.19 | 2023 | Inspire |
| Tms Neurohealth Centers INC. | $27.90 | 2025 | Tms Neurohealth Centers INC. |
| Xeris Pharmaceuticals, INC. | $22.88 | 2021 | |
| Genzyme Corporation | $22.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.60 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.10 | 2022 | |
| Corcept Therapeutics | $15.49 | 2024 | Korlym |
| Ironwood Pharmaceuticals, INC | $14.94 | 2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandip Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.